Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160177 | 0.91 | PPARG (0.95) | PPARGLMNA | |
| SCHEMBL1160358 | 0.90 | PPARG (0.78) | PPARGLMNAPOLB | |
| SCHEMBL6300036 | 0.89 | PPARG (0.79) | PPARGLMNA | |
| Atx08-001 SCHEMBL29368164 | 0.89 | PPARG (1.00) | PPARGLMNA | |
| Atx08-001 SCHEMBL682052 | 0.89 | PPARG (1.00) | PPARGLMNA | |
| Atx08-001 SCHEMBL29691565 | 0.89 | PPARG (1.00) | PPARGLMNA | |
| SCHEMBL1160468 | 0.87 | PPARG (0.73) | PPARGLMNAPOLB | |
| SCHEMBL1178512 | 0.84 | PPARG (0.82) | PPARG | |
| SCHEMBL7650777 | 0.84 | PPARG (0.91) | PPARG | |
| SCHEMBL5881969 | 0.84 | PPARG (0.71) | PPARGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563589-B2 | Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma | SAMEEVE CORP | 2013-10-22 | — | — | US | disclosed |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| CN-1211238-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-03-17 | — | — | CN | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885LMNA 2259/4885POLB 2157/4885 |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885LMNA 2259/4885POLB 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.